Intratumoral activation of cyclophosphamide by retroviral transfer of the cytochrome P45O 2B1 in a pancreatic tumor model. Combination with the HSVtk/GCV system

Journal of Gene Medicine

Volumn 4, Issue 2, 2002, Pages 141-149

  Carrió, Meritxell ^a   Visa, Joana ^a,c   Cascante, Anna ^a,b   Estivill, Xavier ^a,b   Fillat, Cristina ^a,b  

^a Institut de Recerca Oncologica   (Spain)

^b CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^c Barcelona Science Park   (Spain)

Author keywords

Cytochrome P450 2B1; Gene therapy; Pancreatic cancer; Retrovirus; Thymidine kinase

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B1; GANCICLOVIR; RETROVIRUS VECTOR; SODIUM CHLORIDE; THYMIDINE KINASE; ALKYLATING AGENT; ANTIVIRUS AGENT; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BYSTANDER EFFECT; CANCER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE TRANSFER; GENETIC CODE; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SUICIDE GENE; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENE; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIFFERENTIATION; CULTURE MEDIUM; DOSE RESPONSE; GENETICS; METABOLISM; NUDE MOUSE; RETROVIRUS; TIME;

ANIMALIA; HERPES; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTIVIRAL AGENTS; CELL DIFFERENTIATION; CULTURE MEDIA, CONDITIONED; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP2B1; DOSE-RESPONSE RELATIONSHIP, DRUG; GANCICLOVIR; GENE TRANSFER TECHNIQUES; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PRODRUGS; RETROVIRIDAE; THYMIDINE KINASE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036519244     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.247     Document Type: Article

References (33)

1. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-465.
2. Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs 2000; 59: 1071-1089.
3. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
4. Cheng YC, Huang ES, Lin JC, et al. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci U S A 1983; 80: 2767-2770.
5. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
6. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000; 60 3989-3999.
7. Vrionis FD, Wu JK, Qi P, et al. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther 1997; 4: 577-585.
8. Carrió M, Mazo M, López-Iglesias C, et al. Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells results in variable efficency on the bystander killing: implications for gene therapy. Int J Cancer 2001; 94: 81-88.
9. Rosenfeld ME, Vickers SM, Raben D, et al. Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene. Ann Surg 1997; 225: 609-618.
10. DiMaio JM, Clary BM, Via DF, et al. Directed enzyme prodrug gene therapy for pancreatic cancer in vivo. Surgery 1994; 116: 205-213.
11. Ohashi M, Kanai F, Tanaka T, et al. In vivo adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing pancreatic cancer. Jpn J Cancer Res 1998; 89 457-462.
12. Carrio M, Romagosa A, Mercade E, et al. Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene. Gene Ther 1999; 6: 547-553.
13. Davidoff AN, Mendelow BV. Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide. Exp Hematol 1993; 21: 922-927.
14. Wei MX, Tamiya T, Chase M, et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994; 5: 969-978.
15. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995; 55: 581-589.
16. Chen L, Waxman DJ, Chen D, Kufe DW. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 1996; 56: 1331-1340.
17. Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/eytosine deaminase gene therapies [see comments]. J Natl Cancer Inst 1998; 90: 370-380.
18. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-1333.
19. Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997; 8: 73-85.
20. Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999; 59: 3861-3865.
21. Reyes G, Villaneuva A, Garcia C, et al. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res 1996; 56: 5713-5719.
22. Doehmer J, Dogra S, Friedberg T, et al. Stable expression of rat cytochrome P-450IIB1 cDNA in Chinese hamster cells (V79) and metabolic activation of aflatoxin B1. Proc Natl Acad Sci U S A 1988; 85: 5769-5773.
23. Izquierdo M, Martin V, de Felipe P, et al. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther 1996; 3: 491-495.
24. Onodera M, Yachie A, Nelson D, Welchlin HM, Morgan R, Blaese RMA. Simple and reliable method for screening retroviral producer clones without selectable markers. Hum Gene Ther 1997; 8: 1189-1194.
25. Genka S, Deutsch J, Stahle PL, et al. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Chemother Pharmacol 1990; 27 1-7.
26. Hodgson AV, White TB, White JW, Strobel HW. Expression analysis of the mixed function oxidase system in rat brain by the polymerase chain reaction. Mol Cell Biochem 1993; 120: 171-179.
27. Lohr M, Muller P, Karle P, et al. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther 1998; 5: 1070-1078.
28. Lohr M, Bago Z, Bergmeister H, et al. Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study. J Mol Med 1999; 77: 393-398.
29. Kuriyama S, Masui K, Kikukawa M, et al. Complete cure of established murine hepatocellular carcinoma is achievable by repeated injections of retroviruses carrying the herpes simplex virus thymidine kinase gene. Gene Ther 1999; 6: 525-533.
30. Ishikawa H, Petros W, Ludeman SM, et al. intraneoplasic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res 2001; 61: 864-868.
31. Stohrer M, Boucher Y, Stangassinger M, Jain RK, Oncotic pressure in solid tumors is elevated. Cancer Res 2000; 60: 4251-4255.
32. Andersson BS, Sadeghi T, Siciliano MJ, Legerski R, Murray D. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol 1996; 38 406-416.
33. Ilsley DD, Lee SH, Miller WH, Kuchta RD. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry 1995; 34: 2504-2510.